Literature DB >> 22072157

Reversible severe deterioration of glycaemic control after withdrawal of metformin treatment.

Z Panossian, P L Drury, T Cundy.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 22072157     DOI： 10.1007/s00125-011-2351-x

Source DB:  PubMed          Journal:  Diabetologia        ISSN： 0012-186X            Impact factor:   10.122


× No keyword cloud information.
  9 in total

1.  A modified Cockcroft-Gault formula taking into account the body surface area gives a more accurate estimation of the glomerular filtration rate.

Authors:  Guy Rostoker; Pierre Andrivet; Isabelle Pham; Mireille Griuncelli; Serge Adnot
Journal:  J Nephrol       Date:  2007 Sep-Oct       Impact factor: 3.902

Review 2.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus.

Authors:  Shelley R Salpeter; Elizabeth Greyber; Gary A Pasternak; Edwin E Salpeter
Journal:  Cochrane Database Syst Rev       Date:  2010-04-14

Review 3.  Clinical pharmacokinetics of metformin.

Authors:  A J Scheen
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

Review 4.  Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review.

Authors:  Dean T Eurich; Finlay A McAlister; David F Blackburn; Sumit R Majumdar; Ross T Tsuyuki; Janice Varney; Jeffrey A Johnson
Journal:  BMJ       Date:  2007-08-30

5.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

6.  Discontinuation of metformin in type 2 diabetes patients treated with insulin.

Authors:  M G Wulffelé; A Kooy; P Lehert; D Bets; J A Oom; B Borger van der Burg; A J M Donker; C D A Stehouwer
Journal:  Neth J Med       Date:  2002-07       Impact factor: 1.422

7.  Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

Authors:  R A DeFronzo; A M Goodman
Journal:  N Engl J Med       Date:  1995-08-31       Impact factor: 91.245

8.  Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes.

Authors:  Kaixin Zhou; Celine Bellenguez; Chris C A Spencer; Amanda J Bennett; Ruth L Coleman; Roger Tavendale; Simon A Hawley; Louise A Donnelly; Chris Schofield; Christopher J Groves; Lindsay Burch; Fiona Carr; Amy Strange; Colin Freeman; Jenefer M Blackwell; Elvira Bramon; Matthew A Brown; Juan P Casas; Aiden Corvin; Nicholas Craddock; Panos Deloukas; Serge Dronov; Audrey Duncanson; Sarah Edkins; Emma Gray; Sarah Hunt; Janusz Jankowski; Cordelia Langford; Hugh S Markus; Christopher G Mathew; Robert Plomin; Anna Rautanen; Stephen J Sawcer; Nilesh J Samani; Richard Trembath; Ananth C Viswanathan; Nicholas W Wood; Lorna W Harries; Andrew T Hattersley; Alex S F Doney; Helen Colhoun; Andrew D Morris; Calum Sutherland; D Grahame Hardie; Leena Peltonen; Mark I McCarthy; Rury R Holman; Colin N A Palmer; Peter Donnelly; Ewan R Pearson
Journal:  Nat Genet       Date:  2010-12-26       Impact factor: 38.330

Review 9.  Use of metformin in the setting of mild-to-moderate renal insufficiency.

Authors:  Kasia J Lipska; Clifford J Bailey; Silvio E Inzucchi
Journal:  Diabetes Care       Date:  2011-06       Impact factor: 19.112
  9 in total
  2 in total

1.  Metformin Benefits: Another Example for Alternative Energy Substrate Mechanism?

Authors:  Andrea Giaccari; Anna Solini; Simona Frontoni; Stefano Del Prato
Journal:  Diabetes Care       Date:  2021-03       Impact factor: 19.112

2.  Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials.

Authors:  Ralph A DeFronzo; John B Buse; Terri Kim; Colleen Burns; Sharon Skare; Alain Baron; Mark Fineman
Journal:  Diabetologia       Date:  2016-05-23       Impact factor: 10.122
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.